WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206107
CAS#: 1229208-44-9
Description: Entospletinib, also known as GS-9973, is a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications. In Phase II clinical trials, Entospletinib demonstrates clinical activity in subjects with relapsed or refractory CLL with acceptable toxicity.
Hodoodo Cat#: H206107
Name: Entospletinib
CAS#: 1229208-44-9
Chemical Formula: C23H21N7O
Exact Mass: 411.18
Molecular Weight: 411.460
Elemental Analysis: C, 67.14; H, 5.14; N, 23.83; O, 3.89
Synonym: Entospletinib; GS9973; GS 9973; GS-9973.
IUPAC/Chemical Name: 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine
InChi Key: XSMSNFMDVXXHGJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
SMILES Code: C12=NC=CN1C=C(C3=CC4=C(C=C3)C=NN4)N=C2NC5=CC=C(N6CCOCC6)C=C5
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Entospletinib (GS-9973) is a Syk inhibitor with an IC50 of 7.7 nM. |
| In vitro activity: | The effects of a Btk inhibitor, tirabrutinib, and a Syk inhibitor, entospletinib, were investigated alone and in combination on platelet signaling and functions in vitro. Entospletinib alone efficiently inhibited washed platelet aggregation in response to collagen. However, entospletinib only weakly affected platelet activation in platelet-rich plasma. Importantly, the combination of tirabrutinib and entospletinib induced a significant decrease in platelet response to collagen in vitro. Reference: J Thromb Haemost. 2020 Dec;18(12):3336-3351. https://onlinelibrary.wiley.com/doi/10.1111/jth.15098 |
| In vivo activity: | Potential utility of ENTO (Entospletinib) as GVHD (graft-versus-host disease) prophylaxis was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. Early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Reference: JCI Insight. 2018 Oct 4;3(19):e122430. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237454/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 34.5 | 83.85 | |
| DMSO:PBS (pH 7.2) (1:2) | 0.3 | 0.73 |
The following data is based on the product molecular weight 411.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Series J, Ribes A, Garcia C, Souleyreau P, Bauters A, Morschhauser F, Jürgensmeier JM, Sié P, Ysebaert L, Payrastre B. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. J Thromb Haemost. 2020 Dec;18(12):3336-3351. doi: 10.1111/jth.15098. Epub 2020 Oct 26. PMID: 32926549. 2. Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight. 2018 Oct 4;3(19):e122430. doi: 10.1172/jci.insight.122430. PMID: 30282825; PMCID: PMC6237454. |
| In vitro protocol: | 1. Series J, Ribes A, Garcia C, Souleyreau P, Bauters A, Morschhauser F, Jürgensmeier JM, Sié P, Ysebaert L, Payrastre B. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. J Thromb Haemost. 2020 Dec;18(12):3336-3351. doi: 10.1111/jth.15098. Epub 2020 Oct 26. PMID: 32926549. |
| In vivo protocol: | 1. Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight. 2018 Oct 4;3(19):e122430. doi: 10.1172/jci.insight.122430. PMID: 30282825; PMCID: PMC6237454. |
1: Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. doi: 10.1182/blood-2014-08-595934. Epub 2015 Feb 18. PubMed PMID: 25696919; PubMed Central PMCID: PMC4401348.
